| 前收盘价格 | 12.86 |
| 收盘价格 | 12.81 |
| 成交量 | 1,711,475 |
| 平均成交量 (3个月) | 1,282,919 |
| 市值 | 1,027,055,872 |
| 价格/销量 (P/S) | 126.01 |
| 股市价格/股市净资产 (P/B) | 4.51 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2026 |
| 营业毛利率 | -261.91% |
| 营业利益率 (TTM) | -199.72% |
| 稀释每股收益 (EPS TTM) | -2.42 |
| 季度收入增长率 (YOY) | 109.30% |
| 总债务/股东权益 (D/E MRQ) | 8.07% |
| 流动比率 (MRQ) | 7.85 |
| 营业现金流 (OCF TTM) | -148.18 M |
| 杠杆自由现金流 (LFCF TTM) | -82.41 M |
| 资产报酬率 (ROA TTM) | -29.16% |
| 股东权益报酬率 (ROE TTM) | -53.54% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | EyePoint, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.8
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.83 |
|
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 3.46% |
| 机构持股比例 | 109.22% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合